Cariprazine (trade name Vraylar, previously known as RGH-188) is an antipsychotic drug developed by Gedeon Richter. It acts as a D2 and D3 receptor partial agonist, with high selectivity towards the D3 receptor. Positive Phase III study results were published for schizophrenia and mania in early 2012, and for bipolar disorder I depression from a Phase II trial in 2015. Action on the dopaminergic systems makes it also potentially useful as an add-on therapy in major depressive disorder ; Rights are currently owned by Gedeon Richter and Actavis. The drug received FDA approval on September 17, 2015.

CAS：839712-12-8
中文别名：
英文别名：Cariprazine;trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3,3-dimethyl-urea;Cariprazine (USAN/INN);3-(trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea;trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine;RGH 188;UNII-F6RJL8B278;trans 4-{2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine;
分子式：C21H32Cl2N4O
分子量：427.411
精确质量：426.195
Psa：42.31
Logp：4.5428

UNII：F6RJL8B278

密度：1.2±0.1g/cm3
沸点：600.1±55.0°Cat760mmHg
闪点：316.7±31.5°C
蒸汽压：0.0±1.7mmHgat25°C
折射率：1.595
储存条件：-20°C